**Chapter 6**

*Monoclonal Antibodies*

Sci Rep. 2017;7:45259.

Hosseinzadeh G, Arezumand R. Rational affinity enhancement of fragmented antibody by ligand-based affinity improvement approach. Biochemical and Biophysical Research Communications. 2018;506:653-9.

assessment of oxidation via middledown LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodies. MAbs. 2017;9(4):646-53.

[128] Agrawal NJ, Dykstra A, Yang J, Yue H, Nguyen X, Kolvenbach C, et al. Prediction of the Hydrogen Peroxide-Induced Methionine Oxidation

Propensity in Monoclonal Antibodies. J

[129] Plotnikov NV, Singh SK, Rouse JC, Kumar S. Quantifying the Risks of Asparagine Deamidation and Aspartate Isomerization in Biopharmaceuticals

Pharm Sci. 2018;107(5):1282-9.

by Computing Reaction Free-Energy Surfaces. J Phys Chem B.

[130] Jia L, Sun Y. Protein asparagine deamidation prediction based on structures with machine learning methods. PLoS One.

[131] Delmar JA, Wang J, Choi SW, Martins JA, Mikhail JP. Machine Learning Enables Accurate Prediction of Asparagine Deamidation Probability and Rate. Mol Ther Methods Clin Dev.

[132] Sankar K, Hoi KH, Yin Y, Ramachandran P, Andersen N, Hilderbrand A, et al. Prediction of methionine oxidation risk in monoclonal antibodies using a machine learning method. MAbs.

[133] Aledo JC, Canton FR, Veredas FJ. A machine learning approach for predicting methionine oxidation sites. Bmc Bioinformatics. 2017;18(1):430.

2017;121(4):719-30.

2017;12(7):e0181347.

2019;15:264-74.

2018;10(8):1281-90.

[120] Julian MC, Li L, Garde S, Wilen R, Tessier PM. Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability.

[121] Kazlauskas R. Engineering more stable proteins. Chemical Society reviews. 2018;47(24):9026-45.

[122] Wang X, Das TK, Singh SK, Kumar S. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.

[123] Agrawal NJ, Kumar S, Wang X, Helk B, Singh SK, Trout BL. Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions. J Pharm Sci. 2011;100(12):5081-95.

MAbs. 2009;1(3):254-67.

[124] Kumar S, Plotnikov NV,

2018;70(5):595-608.

[125] Lu X, Nobrega RP,

Immunology. 2017;8.

Rouse JC, Singh SK. Biopharmaceutical Informatics: supporting biologic drug development via molecular modelling and informatics. The Journal of pharmacy and pharmacology.

Lynaugh H, Jain T, Barlow K, Boland T, et al. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. MAbs. 2019;11(1):45-57.

[126] Li W, Zhu ZY, Chen WZ, Feng Y, Dimitrov DS. Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development. Frontiers in

[127] Yang R, Jain T, Lynaugh H,

Nobrega RP, Lu X, Boland T, et al. Rapid

**126**
